Brief: Kazia Therapeutics Reports 100% Clinical Benefit Rate In Initial Six Patients Treated For Advanced Triple-Negative Breast Cancer
27/08/2026 21:32
BRIEF-Kazia Therapeutics Reports 100% Clinical Benefit Rate In Initial Six Patients Treated For Advanced Triple-Negative Breast Cancer Aug 27 (Reuters) - Kazia Therapeutics Ltd KZIA.O:
KAZIA THERAPEUTICS REPORTS 100% CLINICAL BENEFIT RATE IN INITIAL SIX PATIENTS TREATED FOR ADVANCED TRIPLE-NEGATIVE BREAST CANCER
KAZIA THERAPEUTICS - REPORTS 83% OBJECTIVE RESPONSE RATE IN SIX PATIENTS
KAZIA THERAPEUTICS - ALL PATIENTS SHOW MEDIAN 83% REDUCTION IN CTC CLUSTERS, 51% IN EXHAUSTED T CELLS
KAZIA THERAPEUTICS - NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS OBSERVED
KAZIA THERAPEUTICS - PHASE 1B STUDY ENROLLMENT EXPECTED TO COMPLETE BY JULY 2027, WITH INTERIM CLINICAL UPDATES ANTICIPATED THROUGHOUT 2026 AND 2027
Source text: ID:nPn1dC2M5a
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering